4D Path Announces New Data Highlighting Efficacy of the Q-plasia OncoReader (QPOR™) Platform
Newton, Massachusetts, May 30, 2024: 4D Path (“the Company”), a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response,…